These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 27609424)

  • 1. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
    Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
    Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan.
    Igarashi A; Tang W; Cure S; Guerra I; Marié L; Lopresti M; Tsutani K
    Curr Med Res Opin; 2017 Jan; 33(1):1-10. PubMed ID: 27608157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
    Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective.
    Thokala P; Simpson EL; Tappenden P; Stevens JW; Dickinson K; Ryder S; Harrison P
    Pharmacoeconomics; 2016 Aug; 34(8):741-50. PubMed ID: 26892974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
    Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
    Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
    Tao T; Jiang X; Chen Y; Song Y
    Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
    J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
    Ruggeri M; Rolli FR; Kondili LA; Drago C; De Solda F; Nappi C; Cicchetti A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):363-374. PubMed ID: 30351994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
    Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH
    Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    Suda G; Ogawa K; Yamamoto Y; Katagiri M; Furuya K; Kumagai K; Konno J; Kimura M; Kawagishi N; Ohara M; Umemura M; Ito J; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Tsubota A; Shimada N; Iio E; Tanaka Y; Sakamoto N;
    J Gastroenterol; 2017 Oct; 52(10):1122-1129. PubMed ID: 28315983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
    Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
    Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
    Saab S; Parisé H; Virabhak S; Wang A; Marx SE; Sanchez Gonzalez Y; Misurski D; Johnson S
    J Med Econ; 2016 Aug; 19(8):795-805. PubMed ID: 27063573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
    Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S
    Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
    Elsisi GH; Aburawash A; Waked E
    Value Health Reg Issues; 2017 Sep; 13():7-15. PubMed ID: 29073993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
    J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
    Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
    Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.
    Zhou HJ; Cao J; Shi H; Naidoo N; Semba S; Wang P; Fan YF; Zhu SC
    Front Public Health; 2021; 9():779215. PubMed ID: 34957030
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan.
    Virabhak S; Yasui K; Yamazaki K; Johnson S; Mitchell D; Yuen C; Samp JC; Igarashi A
    J Med Econ; 2016 Dec; 19(12):1144-1156. PubMed ID: 27348464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
    Buggisch P; Vermehren J; Mauss S; Günther R; Schott E; Pathil A; Boeker K; Zimmermann T; Teuber G; Vornkahl HP; Simon KG; Niederau C; Wedemeyer H; Zeuzem S
    J Hepatol; 2018 Apr; 68(4):663-671. PubMed ID: 29133244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
    Modi AA; Nazario HE; Gonzales GR; Gonzalez SA
    Aliment Pharmacol Ther; 2018 May; 47(10):1409-1415. PubMed ID: 29569736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.